Dysregulation of deubiquitinylases: a linchpin of gastrointestinal diseases
Lorena Ferino,
No information about this author
Michael Naumann
No information about this author
Trends in Molecular Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Language: Английский
Caspase 3-specific cleavage of ubiquitin-specific peptidase 48 enhances drug-induced apoptosis in AML
Zhanglin Zhang,
No information about this author
Xiang Lin,
No information about this author
Ya‐Ling Yang
No information about this author
et al.
Cancer Biology & Therapy,
Journal Year:
2025,
Volume and Issue:
26(1)
Published: Jan. 29, 2025
Dysfunction
or
dysregulation
of
deubiquitination
is
closely
related
to
the
initiation
and
development
multiple
cancers.
Targeted
regulation
has
been
recognized
as
an
important
strategy
in
tumor
therapy.
However,
mechanism
by
which
drugs
regulate
deubiquitinase
not
clear.
Here,
we
identified
ubiquitin-specific
peptidase
48
(USP48),
a
member
protease
family
highly
expressed
various
tumors,
specific
substrate
for
activated
caspase-3.
During
drug
induced
apoptosis
AML
cells,
caspase-3
cleaves
USP48
through
recognizing
conservative
motif
DEQD
located
at
611–614
sites
human
USP48.
Subsequent
analysis
showed
that
cleavage
N-terminal
fragment
contains
catalytic
active
domain
easily
degraded
ubiquitination.
Meanwhile
knockdown
experiment
inhibiting
expression
could
also
promotes
enhance
efficacy
chemotherapy
drugs.
Altogether,
these
results
suggest
targeting
may
represent
novel
therapeutic
AML.
Language: Английский
USP48 inhibits colorectal cancer progression and promotes M1-like macrophage polarization by stabilizing TAK1
Xinwen Zhang,
No information about this author
Jiawei Zhao,
No information about this author
Guangying Qi
No information about this author
et al.
Experimental Cell Research,
Journal Year:
2025,
Volume and Issue:
446(1), P. 114469 - 114469
Published: Feb. 18, 2025
Language: Английский
CDK1-mediated phosphorylation of USP37 regulates SND1 stability and promotes oncogenesis in colorectal cancer
Acta Pharmaceutica Sinica B,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Language: Английский
Therapeutic potential of targeting ubiquitin-specific proteases in colorectal cancer
Chern Ein Oon,
No information about this author
Padmanabhan Anbazhagan,
No information about this author
Chong Teik Tan
No information about this author
et al.
Drug Discovery Today,
Journal Year:
2025,
Volume and Issue:
unknown, P. 104356 - 104356
Published: April 1, 2025
Language: Английский
USP39 promote post-translational modifiers to stimulate the progress of cancer
Yuli Zhou,
No information about this author
Fang Wang,
No information about this author
Siren Feng
No information about this author
et al.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: May 13, 2025
Language: Английский
A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(11), P. 4819 - 4831
Published: Sept. 14, 2024
Colorectal
cancer
(CRC)
is
a
prevalent
malignant
tumor
often
leading
to
liver
metastasis
and
mortality.
Despite
some
success
with
PD-1/PD-L1
immunotherapy,
the
response
rate
for
colon
patients
remains
relatively
low.
This
closely
related
immunosuppressive
microenvironment
mediated
by
tumor-associated
macrophages
(TAMs).
Our
previous
work
identified
that
phosphoglycerate
mutase
1
(PGAM1)
allosteric
inhibitor,
HKB99,
exerts
range
of
anti-tumor
activities
in
lung
cancer.
Here,
we
found
upregulation
Language: Английский
USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1
Wenwen CHEN,
No information about this author
Siqi Wu,
No information about this author
Yifan Chen
No information about this author
et al.
Neoplasia,
Journal Year:
2024,
Volume and Issue:
60, P. 101102 - 101102
Published: Dec. 13, 2024
Language: Английский
UBE2G2 inhibits vasculogenic mimicry and metastasis of uveal melanoma by promoting ubiquitination of LGALS3BP
Andi Zhao,
No information about this author
Chenyu Zhou,
No information about this author
Jin-Jing Li
No information about this author
et al.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(12), P. 5201 - 5218
Published: Sept. 13, 2024
Uveal
melanoma
(UM)
poses
a
significant
lethality,
with
approximately
50%
of
those
developing
metastases
surviving
less
than
one
year.
In
the
progression
UM,
vasculogenic
mimicry
(VM)
induced
by
hypoxia
plays
pivotal
role,
which
also
partially
explains
resistance
UM
to
anti-angiogenic
therapies.
Nevertheless,
crucial
molecular
mechanisms
underlying
VM
in
remain
unclear.
We
identified
ubiquitin
conjugating
enzyme
E2
G2
(UBE2G2)
as
critical
suppressor
through
transcriptomic
sequencing
and
metastasis
correlation
screening.
hypoxia-induced
are
markedly
exacerbated
UBE2G2
knockdown
significantly
alleviated
its
overexpression.
Mechanistically,
directly
binds
galectin
3
binding
protein
(LGALS3BP)
forms
complex
E3
ligase
tripartite
motif
containing
38
(TRIM38),
facilitating
ubiquitination-mediated
degradation
LGALS3BP
at
K104
residue.
Furthermore,
inhibits
oncogenic
phenotypes
inactivating
intracellular
PI3K/AKT
signaling
reprogramming
tumor
microenvironment.
Therefore,
targeting
intercellular
hypoxia-UBE2G2-LGALS3BP
axis
may
contribute
various
therapeutic
strategies
for
UM.
Language: Английский